Document:

EX-10.12

 Exhibit 10.12 

CONSULTING AGREEMENT 

This Consulting Agreement (this “Agreement”), dated as of February 18, 2014, is entered into by and
between Aeglea Development Company, Inc., a Delaware corporation (the “Company”), and George Georgiou (“Consultant”). 

RECITALS 
 A. The Company
is one of several wholly-owned subsidiaries of Aeglea BioTherapeutics Holdings, LLC (“Parent”). 
 B. The Company is
desirous of retaining the services of Consultant, and Consultant has agreed to provide certain services, as described herein, to the Company. 

C. The Company and Consultant are desirous of documenting the terms and conditions of said consulting relationship. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants of the parties set forth herein, IT IS HEREBY AGREED AS
FOLLOWS: 
 SECTION 1: CONSULTING SERVICES 

1.1 Services. Consultant shall perform such consulting, advisory and related services to and for the Company as may be reasonably
requested from time to time by the Company, including, but not limited to, the services specified on Exhibit A to this Agreement (hereinafter referred to as the Consultant’s “Duties”). Consultant will report to
the Chief Executive Officer of the Company. Consultant shall not delegate or subcontract Consultant’s Duties to third parties without the Company’s prior written consent. Consultant shall be available to the Company to perform a total of
twenty one (21) days (eight (8) hours per day) of services per year, travel time included in such hours of service. The amount of hours worked for each monthly period during the term of this Agreement shall be determined by mutual
agreement of the Consultant and the Company. Consultant and the Company acknowledge that Consultant started providing services to the Company on or about December 26, 2013 and those hours performed from that date through the date hereof shall
count toward such hourly maximum. Consultant and the Company acknowledge that Consultant may be a member of the Board of Directors of the Company and its Parent in his capacity as an equity holder on the Parent and that such director seat is not and
will not be considered a service to the Company or Parent, and will not be considered as such under this Agreement or otherwise. 
 1.2
Faculty Membership. The Company acknowledges that Consultant is a member of the faculty of the University of Texas at Austin (the “Institution”); that Consultant is subject to the Institution’s policies, as they
may be revised from time to time, including, among others, policies concerning consulting, conflicts of interests, publications and intellectual property; and that in the event of a specific, irreconcilable conflict between any provision of this
Agreement and an applicable Institution policy, the Institution policy shall govern. 

 1.3 Services for Others. Consultant acknowledges that the services to be performed for the
Company hereunder are essential to the Company and, therefore, except as set forth on the attached Exhibit B, Consultant agrees not to undertake consulting projects without permission from Company for any other party during the term hereof that
pertain to the subject matter of the intellectual property assigned or licensed to the Company regarding arginase 1/ ARG1RefSeg Gene ID: 383 and engineered versions thereof, and cystathionase (cystathionine gamma-lyase)/CTH RefSeg Gene ID: 1491 and
engineered variants thereof including but not limited to Methionase, Cystinase, and any other technology assigned or exclusively licensed to the Company derived from the work performed by Consultant, or other modifications of this technology
exclusively licensed by the Company that, in the reasonable judgment of the Company, would interfere with Consultant’s Duties hereunder. 

1.4 Consideration. The consideration payable to Consultant under this Agreement will include both Consulting Fees and Incentive Shares
(as defined below) as follows, which together shall combine to form the total consideration payable under this Agreement. 
 (a)
Consulting Fees. Consultant shall receive annual consulting fees at the rate of $50,000.00 per year, payable in four (4) equal quarterly installments. 

(b) Incentive Shares. Consultant shall receive a grant of 600,000 Common B Shares of Parent (the “Incentive
Shares”). The Incentive Shares shall be granted pursuant to and under the terms below, the other terms and conditions of Parent’s equity incentive plan and the form of incentive share grant and the Parent’s LLC Agreement as
amended from time to time: The Incentive Shares shall vest as follows: 
 (i) 120,000 Common B Shares shall vest in full on
the date of grant; 
 (ii) 120,000 Common B Shares shall vest on the date that is 18 months from the date hereof (the
“Development Determination Date”) so long as AEMase, Inc. has not returned to GMA LLC the patent applications related to the Methionase program originally contributed to Aeglea BioTherapeutics LLC pursuant to that certain Asset
Contribution Agreement dated April 2, 2013 prior to the Development Determination Date; provided, that, vesting of 60,000 of the 120,000 Common B Shares shall be further conditioned upon obtaining either (i) a consent to assignment from
the National Institutes of Health for the assignment of Serial No. 61/301,368 (the “Methionine Preparations Patent”) by the University of Texas at Austin to Consultant and Everett Stone or (ii) an exclusive license to a
subsidiary of Parent of the Methionine Preparations Patent from the University of Texas at Austin under terms comparable to those in other licenses granted by the University of Texas at Austin to other Parent subsidiaries. 

(iii) 120,000 Common B Shares shall vest on the Development Determination Date so long as the License Agreement between
AECase, Inc. and the University of Texas-Austin for technology related to the Cystinase program has not been terminated prior to the Development Determination Date; 

(iv) 120,000 Common B Shares shall vest upon the first license by a subsidiary of Parent from the University of Texas-Austin
for technology that is unrelated to technology owned or licensed by a subsidiary of Parent involving Arginase, Methionase or Cystinase, such event to occur no later than December 31, 2018; and 

  
 2 

 (v) 120,000 Common B Shares shall vest upon the second license by a subsidiary
of Parent from the University of Texas-Austin for technology that is unrelated to technology owned or licensed by a subsidiary of Parent involving Arginase, Methionase or Cystinase or the technology licensed pursuant to clause (b)(iv) above, such
event to occur no later than December 31, 2018. 
 To the extent there is any discrepancy between this Agreement and the terms of the incentive share
agreement with respect to the terms of the Incentive Shares, this Agreement shall control. To the extent Consultant is granted other incentive shares for other purposes not related to this Consulting Agreement, the provisions therein shall govern
those incentive shares separately from the incentive shares granted herein. 
 1.5 Reimbursement of Expenses. The Company shall also
be responsible for payment of reasonable travel and other customary business expenses incurred by Consultant in the performance of Consultant’s Duties, provided that any such expense in excess of $300 shall be authorized in writing by the
Company prior to the incurring of such expense. The Company will reimburse Consultant for any such expenses reasonably incurred by Consultant upon the presentation by Consultant, from time to time, of a detailed and itemized account of such expenses
substantiated by receipts. 
 1.6 Termination. The term of this Agreement shall commence on the date hereof and shall continue for an
initial period of four (4) years, subject to automatic renewal for additional one (1) month periods thereafter until terminated as hereinafter provided. Either party may terminate this Agreement at any time by delivering written notice
thereof to the other party. Upon any termination Consultant shall be paid any Consulting Fees earned through the date of termination and the Incentive Shares shall remain outstanding subject to the vesting requirements set forth in
Section 1.4(b). 
 1.7 Independent Contractor. This Agreement does not create an employer-employee relationship between the
Company and Consultant. It is the parties’ intention that Consultant will be an independent contractor and not the Company’s employee for any purpose. Consultant will retain sole and absolute discretion and judgment in the manner and means
of carrying out Consultant’s activities and responsibilities hereunder. Consultant and Company agree that Consultant’s business is a separate and independent enterprise from that of the Company, that Consultant has a full opportunity to
find other business, and that Consultant will utilize a high level of skill necessary to perform Consultant’s Duties. Consultant does not have the authority to enter into any contract on behalf of the Company or otherwise to bind the Company to
any agreement unless expressly authorized in writing to do so, and the Company will not be liable for any obligation incurred by Consultant, except as otherwise provided herein. 

Without limiting the foregoing, and except as set forth in Section 1.4(b), Consultant will not be eligible to participate in any
vacation, group medical or life insurance, disability, profit sharing or retirement benefits or any other fringe benefits or benefit plans offered by the Company to its employees, and the Company will not be responsible for withholding or paying any
income, payroll, Social Security or other federal, state or local taxes, making any insurance 

  
 3 

 
contributions, including unemployment or disability, or obtaining worker’s compensation insurance on Consultant’s behalf. Consultant shall be responsible for, and shall indemnify the
Company against, all such taxes or contributions, including penalties and interest. Any persons employed or engaged by Consultant in connection with the performance of the Duties shall be Consultant’s employees or contractors and Consultant
shall be fully responsible for unless these employees or persons engaged are subject to a separate Agreement with Company or are employees of the University of Texas and therefore subject to the rules and regulations of that institution. 

SECTION 2: CONFIDENTIALITY 
 In
consideration of Consultant’s access to the premises of the Company and/or Consultant’s access to certain Confidential Information of the Company, Parent or Parent’s subsidiaries, in connection with Consultant’s business
relationship with the Company, Consultant hereby represents and agrees as follows. 
 2.1 Confidential Information. For purposes of
this Agreement, the term “Confidential Information” means: 
 (a) any information that the Company possesses that
has been created, discovered or developed by or for the Company, Parent or Parent’s subsidiaries, including that information developed by Consultant pursuant to this Agreement, or that has otherwise been made known to the Company and
Consultant, and that has or could have commercial value or utility in the business in which the Company is engaged; or 
 (b) any
information that is related to the business of the Company and is generally not known by non-Company personnel. 
 By way of illustration,
but not limitation, Confidential Information includes all processes, formulas, data, programs, algorithms, know-how, trade secrets, improvements, discoveries, developments, designs, inventions (patentable or not), Biological Materials, mixtures,
techniques, software, source code, object code, marketing plans, strategies, forecasts, new products, financial information, budgets, projections, licenses, prices, costs, and customer and supplier lists. As used in this Agreement, the term
“Biological Materials” means all chemical or biological materials of any kind, including, without limitation, any and all reagents, substances, chemical compounds, proteins or derivatives thereof, subcellular constituents, cells or cell
lines, tissue samples, organisms and progeny, mutants, derivatives or replications thereof or therefrom. 
 2.2 Exclusions.
Notwithstanding the foregoing, the term Confidential Information shall not include: 
 (a) Any information that is or becomes generally
available to the public other than as a result of a breach of the confidentiality portions of this Agreement, or any other agreement requiring confidentiality between the Company and the Consultant; 

(b) Any information received from a third party in rightful possession of such information who is not restricted from disclosing such
information; 

  
 4 

 (c) Any information, the disclosure of which is required by law or court order, provided that
Consultant gives the Company as much prior written notice of any such disclosure as possible and takes all necessary action, or assists Company in taking all necessary action, to minimize the extent of any such disclosure 

(d) Any information whose disclosure is made with the prior written consent of Company; or 

(e) Any information that is independently developed by Consultant prior to or subsequent to the termination of this Agreement with the Company

 2.3 Documents. Consultant agrees that, without the written consent of the Company, Consultant will not remove from the
Company’s premises, any notes, formulas, programs, data, records, machines or any other documents or items that in any manner contain or constitute Confidential Information; nor will Consultant make reproductions or copies of same. In the event
Consultant receives any such documents or items from any officer or director of the Company, or any other Company employee who is Consultant’s supervisor, Consultant shall be deemed to have received the express written consent of the Company.
In the event that Consultant receives any such documents or items, other than as described in the preceding sentence, Consultant agrees to inform the Company promptly of Consultant’s possession of such documents or items. Consultant shall
promptly return any such documents or items, along with any reproductions or copies, to the Company upon the Company’s demand or upon termination of Consultant’s services. 

2.4 No Disclosure or Use. Consultant agrees that Consultant will hold in trust and confidence all Confidential Information and will not
disclose to others, directly or indirectly, any Confidential Information or anything relating to such information without the prior written consent of the Company, except as may be necessary in the course of Consultant’s business relationship
with the Company. Consultant further agrees that Consultant will not use any Confidential Information without the prior written consent of the Company, except as may be necessary in the course of Consultant’s business relationship with the
Company, and that the provisions of this Section 2.4 shall survive termination of this Agreement for a period of five years. 
 2.5
Ownership. 
 (a) Subject to the University of Texas Rules and Regulations and requirements: Consultant agrees that all results from
work performed by Consultant for the Company, including without limitation Confidential Information, whether or not patentable or registrable under copyright or similar statutes or subject to analogous protection (“Inventions”),
shall be the sole and exclusive property of the Company or its nominees, and Consultant will and hereby does assign to the Company all rights in and to such Inventions upon the creation of any such Invention, including, without limitation:
(i) patents, patent applications and patent rights throughout the world; (ii) rights associated with works of authorship throughout the world, including copyrights, copyright applications, copyright registrations, mask work rights, mask
work applications and mask work registrations; (iii) rights relating to the protection of trade secrets and confidential information throughout the world; (iv) rights analogous to those set forth herein and any other proprietary rights
relating to intangible property; and (v) divisions, 

  
 5 

 
continuations, renewals, reissues and extensions of the foregoing (as applicable), now existing or hereafter filed, issued or acquired (collectively, “IP Rights”). The
Company and its nominees shall have the right to use and/or to apply for statutory or common law protections for such Inventions in any and all countries. Consultant hereby waives all claims to moral rights in any Inventions. Consultant further
agrees (I) to assist the Company in every proper way to obtain and from time to time to enforce such IP Rights relating to Inventions, and (II) to execute and deliver to the Company or its nominee upon request all such documents as the Company
or its nominee may reasonably determine are necessary or appropriate, including assignments of inventions. (Such documents may be necessary to: (1) vest in the Company or its nominee clear and marketable title in and to Inventions;
(2) apply for, prosecute and obtain patents, copyrights, mask works rights and other rights and protections relating to Inventions; or (3) enforce patents, copyrights, mask works rights and other rights and protections relating to
Inventions.) Consultant’s obligations pursuant to this Section shall continue beyond the termination of Consultant’s services for the Company. For Consultant’s obligations related to enforcement of patents, patent application work,
patent office appearances, copyrights, mask work rights and other rights and protection relating to Inventions that in all cases involve legal proceedings, Consultant shall be compensated at a rate of $1,000 per hour (including travel time) (the
“Legal Consulting Fee”) based upon an invoice detailing the work performed. Consultant’s obligations pursuant to this Section 2.4 (a) (4) shall be charged at his Legal Consulting Fee. 

(b) Subject to the University of Texas Rules, Regulations, requirements any report or other documentation, whether written or electronic, or
any portions thereof, prepared by Consultant pursuant to this Agreement or which discusses the Invention, Duties performed under this Agreement or the results thereof (the “Written Data”) shall be and is produced as a
“work made for hire” under the copyright laws of the United States. As a “work made for hire”, the copyrights in the Written Data shall belong to Company from their creation and no further action by Company shall be necessary to
perfect Company’s rights therein. All right, title and interest, including any copyright in and to any Written Data that does not qualify as a “work made for hire” shall be and hereby is assigned to Company. Consultant, without
additional compensation, will assign the copyright in all Written Data to Company, as soon as it is fixed and the copyright comes into being. In addition, Consultant agrees to assist Company in taking any subsequent legal steps that may be required
to perfect Company’s copyrights in this Written Data including, but not limited to, executing a formal assignment of copyright that can be recorded. 

(c) Consultant shall require each of its employees and contractors to execute written agreements securing for the Company the rights provided
for in this Section 2.5 prior to such employee or contractor performing any Duties under this Agreement. 
 2.6 Publications.
Consultant agrees to notify Company of any subject matter and provide a copy of any early draft of any manuscript to be published by Consultant or in co- authorship with others, or with the Company’s employees, containing information developed
or disclosed in connection with Consultant’s work for the Company pursuant to this Agreement at least thirty (30) days prior to the submission thereof for publication , and to delay submission thereof upon written notice of any officer of
the Company for a reasonable time period not to exceed sixty (60) days to allow the Company to perfect its interest in any patentable subject matter disclosed therein, or otherwise protect the proprietary rights of the subject information, in a
manner to be determined by the Company. At the end of such period, it is understood that 

  
 6 

 
Consultant shall have the right, subject to such reasonable protections as are required at the sole discretion of the President of the Company, to submit the manuscript for publication.
Notwithstanding any of the foregoing, Consultant shall not be free to publish any Confidential Information provided by Company without the Company’s prior written consent. 

2.7 Consultant Representations. Consultant hereby represents and warrants to Company that (a) Consultant has the right to enter
into this Agreement; (b) it is the sole and exclusive owner of the Inventions and the Written Data, or is a joint owner with other employees or consultants of Company, and has the free, clear, and absolute right to sell, transfer, assign and
convey all rights therein to Company; and (c) it will not bring or cause to be brought a copyright, trademark, patent, trade secret or other proprietary rights infringement suit against Company involving any Invention or Written Data against
Company. 
 2.8 Possession. Consultant agrees that upon termination of this Agreement, or upon request by the Company, Consultant
shall turn over to the Company all documents, files, office supplies and any other material or work product in Consultant’s possession or control that were created pursuant to or derived from Consultant’s services to the Company. 

2.9 Non-Solicitation of Employees. Consultant agrees that during its engagement by the Company and for a period of one (1) year after
termination or cessation of such engagement, Consultant shall not directly or indirectly recruit, solicit or hire any employee of the Company or its affiliates, or induce or attempt to induce any employee of the Company or its affiliates to
discontinue his or her employment relationship with the Company or its affiliates. This section does not apply to University employees who may also be providing services in some manner to the Company or who report to Consultant. 

SECTION 3: MISCELLANEOUS 
 3.1
Saving Provision. The Company and Consultant agree and stipulate that the agreements set out in Section 2 above are fair and reasonably necessary for the protection of the business, goodwill, confidential information, and other
protectable interests of the Company in light of all of the facts and circumstances of the relationship between Consultant and the Company. In the event a court of competent jurisdiction should decline to enforce those provisions, they shall be
deemed to be modified to restrict Consultant to the maximum extent which the court shall find enforceable; however, in no event shall the above provisions be deemed to be more restrictive to Consultant than those contained herein. 

3.2 Injunctive Relief. Consultant acknowledges that the breach or threatened breach of any of the nondisclosure or nonsolicitation
covenants contained herein would give rise to irreparable injury to the Company, which injury would be inadequately compensable in money damages. Accordingly, the Company may seek and obtain a restraining order and/or injunction prohibiting the
breach or threatened breach of any provision, requirement or covenant of this Agreement, in addition to and not in limitation of any other legal remedies which may be available. Consultant further acknowledges and agrees that the agreements set out
above are necessary for the protection of the Company’s legitimate goodwill and business interests and are reasonable in scope and content. 

  
 7 

 3.3 Survival. The provisions of this Agreement relating to nondisclosure, and intellectual
property and the post termination consideration obligations pursuant to Section 1.6 shall survive the termination of this Agreement. 

3.4 Enforcement. The provisions of this Agreement shall be enforceable notwithstanding the existence of any claim or cause of action
against the Company by Consultant or against Consultant by the Company, whether predicated on this Agreement or otherwise. 
 3.5
Governing Law; Jurisdiction. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Texas, excluding that body of law known as choice of law, and shall be binding upon the parties hereto in
the United States and worldwide. 
 3.6 Modification. This Agreement may be modified, and the rights, remedies and obligations
contained in any provision hereof may be waived, only in accordance with this Section. No waiver by either party or any breach by the other or any provision hereof shall be deemed to be a waiver of any later or other breach thereof or as a waiver of
any other provision of this Agreement. This Agreement may not be waived, changed, discharged or terminated orally or by any course of dealing between the parties, but only by an instrument in writing signed by the party against whom any waiver,
change, discharge is sought or by the party notifying of termination of this Agreement. 
 3.7 No Assignment. This Agreement may not
be assigned by Consultant without prior written consent of the Company. Upon any assignment of this Agreement by the Company, the Company shall provide Consultant notice within five (5) business days of such assignment. 

3.8 Entirety. This Agreement, including any exhibits hereto, as it may be amended pursuant to the terms hereof, represents the complete
and final agreement of the parties and shall control over any other statement, representation or agreement by the Company. This Agreement supersedes any prior negotiations or discussions between the parties. 

3.9 Severability. In case any one or more of the provisions contained in this Agreement or the other agreements executed in connection
with the transactions contemplated hereby for any reason shall be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or such other
agreements, but this Agreement or such other agreements, as the case may be, shall be construed and reformed to the maximum extent permitted by law. 

3.10 Binding Effect. This Agreement shall inure to the benefit of Consultant and his heirs, successors, personal representatives and
assigns. Consultant acknowledges that the services to be rendered by him hereunder are unique and personal in nature. Accordingly, Consultant may not assign any of his or her rights or delegate any of his or her duties or obligations under this
Agreement except as provided in this Agreement. The Company shall have the right to assign this Agreement to any successor to all or any substantial part of its or Parent’s business or assets, and any such successor shall be bound by the
provisions hereof. Upon any such assignment of this Agreement by the Company, the Company shall provide Consultant notice within five (5) business days of such assignment. 

  
 8 

 [Signature page follows] 

  
 9 

 IN WITNESS WHEREOF, the undersigned have executed this Consulting Agreement effective as of the
day and year first set forth above. 
  

			
	AEGLEA DEVELOPMENT COMPANY, INC:
		
	By:		 /s/ David G. Lowe

	 Name: David G Lowe
 Title:
President & Chief Executive Officer

	
	CONSULTANT:

 
					
		
	 /s/ George Georgiou
		[SEAL]
	George Georgiou		

 EXHIBIT A 

Duties 
  

	1.	Provide analysis and feedback, either written or oral as requested by the Company, on grant applications, research and development plans, and results arising from such plans for Arginase, Cystinase and Methioninase or
other molecules that may be licensed by the Company or its affiliates from the University of Texas-Austin. 

  

	2.	Travel to attend meetings and or make presentations for Company financing, and fundraising. 

  

	3.	Provide services related to applications for grants from CPRIT or from non-for-profit foundations on behalf of Aeglea and pursuant to the clinical development of Arginase, Cystinase and Methioninase. 

 EXHIBIT B 

Excluded Consulting Projects 
 As of
February 18, 2014, none. 

  
 1EX-10.13

 Exhibit 10.13 

PATENT LICENSE AGREEMENT 

AGREEMENT NO. PM1401601 
 This Patent
License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, ‘Party”). 
 No
binding agreement between the Parties will exist until this Patent License Agreement has been signed by both Parties. Unsigned drafts of this Patent License Agreement shall not be considered offers. 

Background 
 Licensor owns or controls
Patent Rights. Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Patent Rights. Licensor has determined that such use, development, and commercialization of the Patent Rights is in the
public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the Patent Rights developed and used for the benefit of Licensee, the inventors, Licensor, and the public. 

NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the Parties hereby agree as follows: 

The Terms and Conditions of Patent License attached hereto as Exhibit A are incorporated herein by reference in their entirety (the “Terms and
Conditions”). In the event of a conflict between provisions of this Patent License Agreement and the Terms and Conditions, the provisions in this Patent License Agreement shall govern. Unless defined in this Patent License Agreement capitalized
terms used in this Patent License Agreement shall have the meanings given to them in the Terms and Conditions. 
 The section numbers used in the left hand
column in the table below correspond to the section numbers in the Terms and Conditions. 
  

					
	1. Definitions
			
			Effective Date		Date of last signature below
			
			Licensor		The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, an agency of the State of Texas, whose address is 3925 W. Braker Lane, Suite 1.9A (R3500), Austin, Texas 78759.
			
			Licensee		AEMase Inc., a Delaware, C-corporation, which is a wholly owned subsidiary of Aeglea BioTherapeutics Holdings, LLC, a Delaware limited liability corporation, with its principal place of business at 815-A Brazos St., #101, Austin TX
78701

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page 1		Agreement No. PM1401601

					
		  	 Contract Year and

Contract Quarters
	  	(Check one box to correspond with Licensee fiscal year and quarters)
			
		  		  	 x Contract Year is 12-month period ending on December 31 and Contract Quarters are 3-month
periods ending on March 31, June 30, Sept. 30, Dec. 31
 OR
  ̈ Other: Contract Year is 12-month period ending on (specify): [month and day]; Contract Quarters are 3-month periods ending on (specify): [month and day, Q1], [month and day, Q2], [month and day, Q3],
[month and day, Q4]

			
		  	Territory	  	World-wide
			
		  	Field	  	 x All fields

OR
  ̈ Limited
fields
 Field: [Describe field of use] Field: [Describe field of use]

If the Field is not “All Fields” and “Limited fields” is checked, Excluded

Fields include:
 Excluded Field: [Describe excluded field of
use]
 Excluded Field: [Describe excluded field of use]

			
		  	Patent Rights	  	

  

											
	 	  	 App. No./

Date of Filing
	  	 Title
	  	 Inventor(s)
	  	 Jointly Owned?

(Y/N; if Y, with whom?)
	  	 Prosecution Counsel

		  	 61/871,768
 filed

8/29/2013
	  	Engineering Primate L- Methionase for Therapeutic Purposes (6314 GEO)	  	 George Georgiou
 Wei-Cheng Lu
Everett M. Stone
	  	  ̈ Yes, w/[whom]

x No
	  	Parker Highlander PLLC

  

					
		 	 USPTO Entity Status as

of Effective Date
	  	 Check one box:
 x Small
  ̈
Large

  

							
	2.4. Diligence Milestones	  	
				
		  	Milestones and deadlines (see Section 20.1)	  	Milestone Events	  	Deadlines
		  	  	1. [***]	  	[***]
		  	  	2. [***]	  	[***]
		  	  	3. [***]	  	[***]
		  	  	4. [***]	  	[***]
		  	  	5. [***]	  	[***]
		  		  	6. [***]	  	[***]
		  		  	7. [***]	  	[***]
		  		  	8. [***]	  	[***]
		  		  	9. [***]	  	[***]

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.	  	CONFIDENTIAL	  	Exclusive PLA
	The University of Texas at Austin	  	Page 2	  	Agreement No. PM1401601

							
	 3. Compensation
		
				
	 3.1(a)
		Patent expenses due upon Effective Date		Amount		based on invoices received as of:
					$[***]		
				
	 3.1(b)
		Milestone fees		Milestone Events		Milestone Fees
					1. [***]		$[***]
					2. [***]		$[***]
					3. [***]		$[***]
					4. [***]		$[***]
					5. [***]		$[***]
				
	 3.1(c)
		Scheduled license fee payments		[***]		
			
	3.1(d)		Sublicense Fees		 30% of Non-Royalty Sublicensing Consideration from a Sublicense Agreement fully signed prior to December 31, 2014

25% of Non-Royalty Sublicensing Consideration from a Sublicense Agreement fully signed during the Contract Year ending December 31, 2015

20% of Non-Royalty Sublicensing Consideration from a Sublicense Agreement fully signed during the Contract Year ending December 31, 2016

15% of Non-Royalty Sublicensing Consideration from a Sublicense Agreement fully signed during the Contract Year ending December 31, 2017

6.5% of Non-Royalty Sublicensing Consideration from a Sublicense Agreement signed after December 31, 2017

				
	3.1(e)		Assignment Fee		[***]		
				
	3.2		Running royalty rate (applies to Net Sales by Licensee, Affiliates and Sublicensees)		[***]%		

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page 3		Agreement No. PM1401601

					
	18. Contact Information
			Licensee Contacts		Licensor Contacts
			 Contact for Notice:
 Attn:
David G. Lowe
 AEMase Inc.

c/o Aeglea Development

Company
 815-A Brazos St.,
#101
 Austin TX, 78701

Fax: 866 873-2149
 Phone:
[TELEPHONE]
 E-mail: [EMAIL]
  

Accounting contact
 Attn: Charles York

AEMase Inc.
 c/o Aeglea
BioTherapeutics
 Fax: (866) 873-2149

Phone: [TELEPHONE]

E-mail: [EMAIL]
  

Patent prosecution contact:
 Attn: David G.
Lowe
 AEMase Inc.
 c/o
Aeglea Development
 Company

815-A Brazos St., #101

Austin TX, 78701
 Fax: 866
873-2149
 Phone: [TELEPHONE]

E-mail: [EMAIL]
		 Contact for Notice:
 Attn:
Contract Manager
 3925 W. Braker Lane, Suite

1.9A (R3500)
 Austin, TX
78759
 Fax: 512 475-6894

Phone: 512 471-2995

E-mail: licensing@otc.utexas.edu
  

Payment and reporting contact: Checks payable to “The University of Texas at Austin”

Attn: Accounting
 3925 W.
Braker Lane, Suite
 1.9A (R3500)

Austin, TX 78759
 Fax: 512
475-6894
 Phone: 512 471-2995

E-mail:

accounting@otc.utexas.edu
  

Patent prosecution contact:
 Attn: Patents

3925 W. Braker Lane, Suite

1.9A (R3500)
 Austin, TX
78759
 Fax: 512 475-6894

Phone: 512 471-2995

E-mail:

patents@otc.utexas.edu

	For Licensor Administrative Purposes Only
		
	 Changes to Standard
 Form Terms
and
 Conditions
		There have not been any revisions to Licensor’s standard form Terms and Conditions, except for revisions to the following sections: §1, §2.1, §2.1.a, §2.1.b, §2.2, §2.3, §2.3.a-c,
§2.4, §3.1.a-c, §3.1.e, §3.2, §3.2.a-b, §3.3, §3.4, §4, §4.1.c-d, §4.2, §4.2.d, §4.3, §5.3, §5.4, §5.5, §6.1, §6.2, §6.3, §6.4, §7.1, §7.3.c-d,
§7.4.a, §7.5.a-c, §9.1, §9.2, §9.3, §9.4, §10, §11.1, §11.2, §12, §13.1, §13.2, §14.1, §14.2, §15, §16.1, §16.2, §16.3, §17, §19.8

 20. Special Provision. The Parties hereby agree to the following special provisions set forth in this
Section 20 with respect to this Patent License Agreement. 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page 4		Agreement No. PM1401601

	20.1	Commercial Development Milestones. 

 20.1.1 Upon written request from Licensee to
Licensor given prior to the scheduled deadline date to achieve a particular milestone event set forth in Section 2.4, Licensee may request a [***] extension of said milestone deadline date; and said request shall be accompanied by evidence that
demonstrates to Licensor’s reasonable satisfaction that Licensee (and/or its Affiliates and Sublicensees) have been devoting continued diligent efforts to achieve said milestone; and Licensor shall grant the requested extension if Licensor
approves the evidence and efforts, which approval will not be withheld unreasonably. 
 20.1.2 If a first extension has been granted pursuant to
Section 20.1.1 for a particular milestone deadline, Licensee may request a [***] extension for the same milestone deadline, which request shall be made in accordance with the provisions set forth in Section 20.1.1; and if Licensor grants
said request Licensee shall pay $[***] to Licensor as consideration for this second extension, payable within thirty (30) days after Licensee receives written notice that Licensor is willing to grant the extension, which extension will not be
effective if said consideration is not paid by said due date. Any failure to so pay said consideration shall not entitle Licensee to make a later delayed payment during any default cure period that is otherwise specified in this Agreement for curing
other defaults. 
 20.2 Only as long as Licensee is an Affiliate of Aeglea BioTherapeutics Holdings, LLC and has not assigned this Patent License
Agreement to a third party, the definition for “Non-royalty Sublicensing Consideration” shall be the following: [***]. 
 20.3 If the
Parties mutually determine that the rights granted by this License Agreement are essential to the Licensee’s use of any University Invention arising under Sponsored Research Agreement UTA13-001113, then such University Invention shall be
included in this License Agreement upon Licensee’s payment to Licensor of a fee of $[***]. 
 21. No Other Promises and Agreements;
Representation by Counsel. Licensee expressly warrants and represents and does hereby state and represent that no promise or agreement which is not herein expressed has been made to Licensee in executing this Patent License Agreement except
those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not relying upon any statement or representation of Licensor or its representatives. Licensee is relying on Licensee’s own judgment and has had the
opportunity to be represented by legal counsel. Licensee hereby warrants and represents that Licensee understands and agrees to all terms and conditions set forth in this Patent License Agreement and said Terms and Conditions. 

22. Deadline for Execution by Licensee. If this Patent License Agreement is executed first by the Licensor and is not executed by the Licensee
and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within 30 days of the date of signature set forth under the Licensor’s signature below, then this Patent License Agreement
shall be null and void and of no further effect. 
  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page 5		Agreement No. PM1401601

 IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Patent
License Agreement. 
  

									
	 LICENSOR: THE UNIVERSITY OF

TEXAS AT AUSTIN ON BEHALF OF THE
 BOARD OF REGENTS OF
THE
 UNIVERSITY OF TEXAS SYSTEM
				LICENSEE: AEMase Inc.
					
	By		/s/ Daniel W. Sharp				By		/s/ David G. Lowe
	Daniel W. Sharp, J.D.				David G. Lowe
	 Associate Vice President for Research and

Director, Office of Technology
 Commercialization
				President and Chief Executive Officer
					
	Date		12/20/13				Date		12/24/13

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page 6		Agreement No. PM1401601

 EXHIBIT A 

TERMS AND CONDITIONS OF PATENT LICENSE 

These Terms and Conditions of Patent License (“Terms and Conditions”) are incorporated by reference into the Patent License Agreement to which they
are attached. All Section references in these Terms and Conditions shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise. 
  

	1.	Definitions 

 “Affiliate” means with any person, corporation or other
business entity which, directly or indirectly through one or more intermediaries, actually controls, is actually controlled by, or is under common control with a party. As used in this paragraph, “control” means to possess, directly or
indirectly, the power to affirmatively direct the management and policies of such person, corporation or other business entity, whether through ownership of at least fifty percent (50%) of the voting securities or by contract relating to voting
rights or corporate governance. 
 “Agreement” means collectively (i) these Terms and Conditions, and (ii) the
Patent License Agreement. 
 “BLA” means Biological License Application, as defined in the U.S. Federal Food, Drug and
Cosmetic Act and the regulations promulgated thereunder, as well as any equivalent foreign application, registration or certification in the relevant country, such as a Marketing Approval Application in Europe, in each case with respect to a
Licensed Product. 
 “Commercially reasonable efforts” means the expenditure of those efforts and resources used consistent
with the usual practice of similarly situated companies in pursuing development or commercialization of its other similar pharmaceutical products with similar market potential and at a similar stage in development. 

“Contract Quarter” means the three-month periods indicated as the Contract Quarter in Section 1 of the Patent License
Agreement or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement 

“Contract Year” means the 12-month periods indicated as the Contract Year in Section 1 of the Patent License Agreement,
or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement. 

“Covered” means that the use manufacture, sale, offer for sale, development, commercialization or importation of the subject
matter in question by an unlicensed entity would infringe a Valid Claim of a Patent Right. 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-1		Agreement No. PM1401601

 “Cumulative Received Capital” means the total funding received by Licensee and
its Affiliates after the Equity Financing which funding may be received in connection with any type of transaction, including, without limitation, grants, financings, licensing, research and development and strategic collaborations. 

“Effective Date” means the date indicated as the Effective Date in Section 1 of the Patent License Agreement. 

“Equity Financing” means a transaction or series of related transactions in which License and/or its Affiliates receive at
least $[***] in in cumulative proceeds from the sale of equity. 
 “Fair Market Value” means the cash consideration an
unaffiliated, unrelated buyer would pay in an arm’s length sale of a substantially identical item sold in the same quantity, under the same terms, and at the same time and place. 

“Field” means the field indicated as the Field identified in Section 1 of the Patent License Agreement. 

“Government” means any agency, department, unit, or other instrumentality of the United States of America, or any foreign
country, or any province, state, county, city or other political subdivision (including any supra-national agency such as in the European Union). 

“Gross Consideration” means all cash and non-cash consideration (e.g., securities). 

“IND” means an Investigational New Drug Application, as defined in the U.S. Federal Food, Drug and Cosmetic Act and the
regulations promulgated thereunder, or comparable filing in a foreign jurisdiction, in each case with respect to a Licensed Product. 

“Licensed Process” means a method or process whose practice or use is covered by a Valid Claim. 

“Licensed Product” means any product or component (i) whose manufacture, use, sale, offer for sale or import is Covered
by any Valid Claim, or (ii) which is made using a Licensed Process or another Licensed Product. 
 “Licensee” means
the Party identified as the Licensee in Section 1 of the Patent License Agreement. 
 “Licensor” means the Party
identified as the Licensor in Section 1 of the Patent License Agreement. 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-2		Agreement No. PM1401601

 “Milestone Fees” means all fees identified as Milestone Fees in
Section 3.1(b) of the Patent License Agreement. 
 “Net Product Sales” means gross amounts invoiced for
Licensee’s, its Affiliates’, and Sublicensees’ sales of Licensed Products, less the sum of the following, to the extent related to the sale of such Licensed Products: (1) discounts in amounts reasonable or customary in the trade,
including but not limited to trade, cash, consumer, and quantity discounts, and credits, price adjustments or allowances for damaged Licensed Products, returns, defects, recalls or rejections of Licensed Products or retroactive price reductions; (2)
reasonable rebates, credits, and chargeback payments granted to any Government or managed health care organizations, including their agencies, purchasers, and/or reimbursers, under programs available under or required by applicable laws, rules or
regulations, or reasonably entered into to sustain and/or increase market share for Licensed Products; (3) sales, value added, use, excise, and similar taxes (but excluding all types of income tax); (4) amounts allowed or credited on
returns for defective, damaged, expired, or otherwise unuseable or unsaleable Licensed Products; (5) freight, shipping, handling, and insurance charges that are specifically included in the billed amount; and (6) import or export duties,
tariffs, or similar charges incurred with respect to the import or export of Licensed Products into or out of any country. Such amounts shall be determined from the books and records of Licensee, its Affiliates, and Sublicensees maintained in
accordance with such reasonable accounting principles as may be consistently applied by Licensee, its Affiliates, and Sublicensees. 

Licensed Products are considered “sold” when billed out or invoiced or, in the event such Licensed Products are not billed out, or
invoiced, when the consideration for sale of the Licensed Products is received. Notwithstanding the foregoing, Net Product Sales shall not include, and shall be deemed zero with respect to (i) Licensed Products used by Licensee, its Affiliates,
or Sublicensees for their internal use (ii) the distribution of reasonable quantities of free promotional samples of Licensed Products, (iii) Licensed Products provided for clinical trials or research, development, or evaluation purposes,
or 
 (iv) Licensed Products provided by or on behalf of licensee, an Affiliate or a Sublicensee to Licensee, an Affiliate or a Sublicensee
for purposes of resale, provided such resale is subject to a-payments due Licensor under Section 32 of this Agreement. For avoidance of doubt, if Licensee sells a Licensed Product to an Affiliate or Sublicensee for the purpose of the Affiliate
or Sublicensee reselling the Licensed Product the final arms-length transaction sale by the Affiliate or Sublicensee shall be the royalty bearing sales transaction, rather than the intermediary sale(s). 

Notwithstanding anything to the contrary, in the event that any Licensed Product includes any proprietary active pharmaceutical ingredients
(“API”), proprietary drug delivery devices, or other proprietary technologies for which rights to use are not included in the licenses or sublicenses granted under this Agreement (“Other Technologies”) but, with respect to the
Other Technologies, may each or collectively form the basis for a 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-3		Agreement No. PM1401601

 
proprietary product separate from a Licensed Product (a “Combination Licensed Product”), then the Net Product Sales of such Combination Licensed Product in a particular country, for the
purposes of determining royalty payments due to Licensor hereunder, shall be determined by multiplying the Net Product Sales of the Combination Licensed Product in such country by the fraction MA-i-B), where A is the weighted average sale price of
the Licensed Product without the Other Technologies (the “Basic Licensed Product”) when sold separately in finished form in such country, and B is the weighted average sale price(s) of product(s) including the Other Technologies (such
products, “Other Licensed Products”) sold separately in finished form in such country (if there is more than one Other Licensed Product B shall equal the sum of all such Other Licensed Products’ weighted average sale prices in such
country). 
 In the event that, with respect to, any Combination Licensed Product sold in a particular country, the weighted average sale
price of the Basic Licensed Product in such country can be determined but the weighted average sale price(s) of the Other Licensed Product(s) in such country cannot be determined, Net Product Sales for purposes of determining royalty payments for
such Combination Licensed Product in such country shall be calculated by multiplying the Net Product Sales of the Combination Licensed Product in such country by the fraction A/C where A is the weighted average sale price of the Basic Licensed
Product when sold separately in finished form in such country and C is the weighted average sale price of the Combination Licensed Product in such country. 

In the event that, with respect to any Combination Licensed. Product sold in a particular country, the weighted average sale price(s) of the
Other Licensed Product(s) in such country can be determined but the weighted average sale price of the Basic Licensed Product cannot be determined, Net Product Sales for purposes of determining royalty payments shall be calculated by multiplying the
Net Product Sales of the Combination Licensed Product by the formula one (1) minus (B/C) (which may also be written as 1- (B/C)), where B is the weighted average sale price(s) of the Other Licensed Product(s) when sold separately in finished
form in such country and C is the weighted average sale price of the Combination Licensed Product in such country (if there is more than one Other Licensed Product B shall equal the sum of all, such Other Licensed Products’ weighted average
sale prices in such country). 
 In the event that, with respect to any Combination Licensed Product sold in a particular country, the
weighted average sale 
 price(s) in such country of neither the Basic Licensed Product nor the Other Licensed Product(s) in the Combination
Licensed Product can be determined, the Net Product Sales of the Combination Licensed Product shall, for the purposes of determining royalty payments with respect to such Combination Licensed Product, be commercially reasonable and determined by
good faith negotiation between Licensee and Licensor consistent with the ratios and related principles referenced above and based on the relative value of the Basic License Product and the Other Licensed Product included in such Combination Licensed
Product. 
  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-4		Agreement No. PM1401601

 The weighted average sale price for a Basic Licensed Product, Other Licensed Product(s), or
Combination Licensed Product in a particular country shall be calculated once for each Calendar Year and such price shall be used during all applicable royalty reporting periods for such Calendar Year When determining the weighted average sale price
of a Basic Licensed Product, Other Licensed Product(s), or Combination Licensed Product in a particular country, the weighted average sale price shall be calculated by dividing the sales dollars by the units of Basic Licensed Product, Combination
Licensed Product, or Other Licensed Product sold in such country during the twelve (12) months (or the number of months sold in a partial Calendar Year) of that Calendar Year for the respective Basic Licensed Product Other Licensed Product(s),
or Combination Licensed Product For each Calendar Year a reasonably forecasted weighted average sale price will be used for the Basic Licensed Product, Other Licensed Product(s), or Combination Licensed Product which forecasted weighted average sale
price will be for each Calendar Year other than the initial Calendar Year (or portion thereof) during which the Combination Licensed Product is sold, no less than the weighted average sale price for the Basic Licensed Product, Other Licensed
Product(s), or Combination Licensed Product in a particular country calculated for the preceding Calendar Year. Any over or under payment due to a difference between forecasted and actual weighted average sale prices will be paid or credited in the
payment due with respect to the following Calendar Year. 
 Notwithstanding anything to the contrary, in the case of discounts on
“bundles” of separate products or services which include Licensed Products (such “bundles” including but not limited to (i) contingent arrangements involving drugs that share the same NDC (whether the same or different
package sizes), drugs with different NDCs, or drugs and other products or services, (ii) circumstances in which a discount is conditioned on the achievement of some other performance requirement for the Licensed Product or other product or
service (e.g. achievement of market share or placement on a formulary tier), or 
 (iii) otherwise where the resulting price concessions or
discounts are greater than those which would have been available had the bundled products or services been purchased separately or outside the bundled arrangement), Licensee may calculate Net Product Sales and royalties due hereunder by applying a
discount to the price of a Licensed Product equal to the average percentage discount of all products or services of Licensee, its Affiliate(s), or Sublicensee(s) in a particular “bundle”, calculated as follows: 

Average percentage 
 discount on
a            +            [1 (X/Y)] x 100 

particular “bundle” 

where X equals the total discounted price of a particular “bundle” of products or services, and Y equals the sum of the undiscounted
bona fide list prices of each unit of every product or service in such “bundle”. Licensee shall provide Licensor documentation reasonably supporting such average discount with respect to each “bundle.” If a Licensed Product in a
“bundle” is not sold separately, and no bona fide list price exists for such 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-5		Agreement No. PM1401601

 
Licensed Product, Licensee and Licensor shall, for purposes of calculating Net Product Safes and royalties due hereunder, negotiate in good faith a reasonable imputed list price for such Licensed
Product and Net Product Sales. 
 “Non-Royalty Sublicensing Consideration” means subject to Section 20.2 of the Patent
License Agreement, the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee in consideration of the grant of a sublicense under the Patent Rights, including, without limitation, fees for such sublicense or fees for an
option under such sublicense or fees for distribution under such sublicense or assignment fees for the assignment of such sublicense, fees to maintain license rights, and bonus/milestone payments (net of any withholding taxes or similar taxes
imposed by any Government that are not reasonably recoverable by Licensee or any Affiliate thereof), but excluding (a) amounts received as running royalties, a profit share, or other revenue sharing based on sales of Licensed Products for which
Licensor receives a running royalty under Section 3.2, (b) purchase price for Licensee’s stock or other securities not in excess of Fair Market Value, and (c) payments made for Licensee’s or its Affiliates’ performance
after the date of the Sublicense Agreement of any research or development work for any licensed Product (or the reimbursement of any of Licensee’s or its Affiliates’ costs and expenses related to such research or development work) so long
as said payments are not in excess of the Fair Market Value for such work, (d) any payment or reimbursement of any costs for filing, prosecution, maintenance, or defense of any Patent Rights, and (e) other Fair Market Value payments made
by a Sublicensee as consideration for Licensee’s or an Affiliate’s performance of services after the date of Sublicense Agreement or provision of goods. 

“Patent License Agreement” means the particular Patent License Agreement to which these Terms and Conditions are attached and
incorporated into by reference. 
 “Patent Rights” means the Licensor’s rights in (a) the patents and patent
applications listed in Section 1 of the Patent License Agreement; (b) all non-provisional patent applications that claim priority to any provisional application listed in Section 1 of the Patent License Agreement and (c) all
divisionals, continuations, and such claims of continuations-in-part as are entitled to claim priority to the aforesaid patents and/or patent applications, and all reissues, reexaminations, extensions of, and foreign counterparts; and (d) any
patents that issue with respect to the aforesaid patent applications. From time to time during the term of the Agreement upon written agreement by both parties, Licensee and Licensor shall update the list of all patent applications and patents
within the Patent Rights. 
 “Phase II” means a means a human clinical trial of a Licensed Product, including possibly
pharrnacokinetic studies, the principal purpose of which is to make a preliminary determination that such Product is safe in a patient population for its intended use and to obtain sufficient information about such Product’s efficacy to permit
the design of further clinical trials, and generally consistent with 21 CFR §312.21(b). Said trial may be conducted in any country. 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-6		Agreement No. PM1401601

 “Phase III” means a human clinical trial of a Licensed Product, which trial is
designed to: (a) establish that a Licensed Product is safe and efficacious for its intended use (b) define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed;
(c) support regulatory approval of such Licensed Product and (d) be generally consistent with 21 CFR § 312.21(c). Said trial may be conducted in any country. 

“Prosecution Counsel” means the law firm or attorney who is handling the prosecution of the Patent Rights. Prosecution
Counsel as of the Effective Date is identified in Section 1 of the Patent License Agreement. 
 “Quarterly Payment
Deadline” means the day that is 90 days after the last day of any particular Contract Quarter. 
 “Regulatory
Approval” means, with respect to the United States, an NDA, BLA, or IND, any foreign counterparts or equivalents of any of the foregoing, any DMFs, and any other filings or submissions required by or provided by Government relating to the
manufacture, development or commercialization of a Licensed Product 
 “Sublicense Agreement” means any agreement or
arrangement pursuant to which Licensee) grants to any third party any license rights of licensee under the Agreement. 
 “Sublicense
Fee” means the fee specified in Section 3.1(d) of the Patent License Agreement. 
 “Sublicensee” means any
entity to whom an express sublicense has been granted under the Patent Rights. 
 “Territory” means the territory so
indicated as the Territory in Section 1 of the Patent License Agreement. 
 “Valid Claim” means a claim of (i) an
issued and unexpired patent included within the Patent Rights unless the claim has been held unenforceable or invalid by the final, un-reversed, and unappealable decision of a court or other government body of competent jurisdiction, has been
irretrievably abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (ii) a pending patent application
within the Patent Rights to the extent the claim continues to be prosecuted in good faith provided that if a particular claim has not issued within five (5) years of its initial filing, it shall not be considered a Valid Claim for purposes of
this Agreement unless and until such claim is included in an issued patent, notwithstanding the foregoing definition. 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-7		Agreement No. PM1401601

	2.	License Grant and Commercialization 

  

	 	2.1.	Grant 

  

	 	(a)	Licensor grants to Licensee a royalty-bearing exclusive license (with the right to sublicense as set forth in Section 2.3) under Patent Rights for the Field and in the Territory to make, have made, distribute, have
distributed, use; offer for sale, sell, lease, loan, export and/or import Licensed Products. 

  

	 	(b)	This grant is subject to any rights of, or obligations to, the Government as set forth in Section 11.2 (Government Rights). Licensor retains the right to practice the Patent Rights for its non-commercial teaching,
research, education, and other educationally-related purposes, including the right to (i) publish the scientific findings from such research and (ii) grant third party not-for-profit institutions rights under the Patent Rights solely for
non-commercial teaching, research, education, and other educationally-related purposes. In the event Licensor’s Office of Technology Commercialization (“OTC”) becomes aware of a proposed publication by George Georgiou that the OTC
understands is likely to include the Licensed Products, then OTC agrees to use reasonable efforts to submit said publication for review by Licensee in advance of publication and to give due consideration to any responsive comments by Licensee. Said
draft publication shall be treated as Licensor’s Confidential Information pursuant to Section 8 hereof. 

  

	 	(c)	Licensor reserves all rights not expressly granted in the Agreement and disclaims the grant of any implied rights to Licensee. 

  

	 	2.2.	Affiliates 

  

	 	    	Licensee may extend the license granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by the Agreement to the same extent as Licensee. Licensee agrees to deliver such written
agreement to Licensor within 30 calendar days following execution. No additional consideration shall be due to Licensor in connection with such extension. 

  

	 	2.3.	Sublicensing 

  

	 	    	Licensee and its Affiliates have the right to grant sublicenses under the Patent Rights. Each such sublicense must be consistent with the terms of the Agreement, subject to the following: 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		 Page A-8
		Agreement No. PM1401601

	 	(a)	Each Sublicensee shall be a party to a Sublicense Agreement that is consistent with, no less protective of Licensor’s rights than, and does not conflict with, the terms of this Agreement, and shall include terms
and conditions reasonably sufficient to enable Licensee to comply with the terms of this Agreement. Each Sublicense Agreement shall be granted for material consideration. In the event of termination of the Agreement continued sublicense rights shall
be governed by Section 7.5(a) (Effect of Termination). Sublicensees shall have the unlimited right to grant further sublicenses under any sublicense granted by the Licensee or its Affiliates pursuant to this Agreement, provided that (i) a
sublicensee of such Sublicensee shall not have the right to grant further sublicenses without the prior written consent of Licensor, which consent shall not be unreasonably withheld or delayed, (ii) any sub-sublicense complies with the terms of
this section, and (iii) such sub-sublicense is granted only to the extent it is necessary for commercialization of Licensed Products. 

  

	 	(b)	Licensor shall be given a true, complete, and correct copy of each Sublicense Agreement granted by Licensee, Affiliate or Sublicensee, and any modification or termination thereof, within 30 days following the applicable
execution of the respective Sublicense Agreement or any amendment to such Sublicense Agreement, and notwithstanding anything to the contrary herein, such Sublicense Agreement shall be deemed Licensee’s Confidential Information. If the
Sublicense Agreement is not in English, Licensee shall provide Licensor an accurate English translation of the sublicense. 

  

	 	(c)	Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all of the Licensee’s duties and obligations contained in the Agreement, including without limitation the payment
of running royalties due under Section 3.2 whether or not paid to Licensee by a Sublicensee. 

  

	 	2.4.	Diligent Commercialization 

  

	 	    	Licensee by itself or through its Affiliates and Sublicensees will use commercially reasonable efforts to research, develop and commercialize at least one Licensed Product in the Field in the Territory. Without limiting
the foregoing, Licensee will fulfill the milestone events specified in Section 2A of the Patent License Agreement by the deadlines indicated therein and (c) use diligent and commercially reasonable efforts to perform and complete the plans
described in the annual report submitted pursuant to Section 4.2 (Annual Written Progress Report). Licensor hereby agrees that the efforts of Sublicensees, Affiliates, and any third party contractors shall be deemed the acts of Licensee for
purposes of satisfying this Section 2.4, and for the purposes of fees due under Section 3.1(b) of the Patent License Agreement. 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-9		Agreement No. PM1401601

	3.	Compensation 

  

	    	In consideration of rights granted to Licensee, Licensee will pay Licensor the following fees and royalties. All fees and royalties are not refundable and are not creditable against other fees and royalties. Each
payment will reference the Patent License Agreement number and will be sent to Licensor’s payment and accounting contact in Section 18 (Notices) of the Patent License Agreement. 

 

	 	3.1.	Non-Royalty Payments due from Licensee 

  

	 	(a)	Patent Expenses. Licensee will reimburse Licensor for the past patent expenses stated in Section 3.1(a) of the Patent License Agreement within 30 days after the Effective Date. The stated amount is the
current estimate for past patent expenses based on invoices received by the Licensor through the stated date. 

  

	 	    	Licensee’s obligations to pay all past and future patent expenses pursuant to Section 6 (Patent Expenses and Prosecution) will not be limited by such amount, provided, however, that in no event shall patent
expenses incurred prior to the Effective Date for which Licensee is responsible exceed $[***]. 

  

	 	(b)	Milestone Fees. Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent License Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth
in Section 3.1(b) of the Patent License Agreement are achieved. Notwithstanding anything to the contrary, each Milestone Fee is payable only once under this Agreement, with respect to the initial accomplishment thereof, regardless of the number
of Licensed Products (or indications therefor) or the number of times such milestone may be achieved. 

  

	 	(c)	Scheduled License Fees. Licensee will pay license fees in the amounts set forth in Sections 3.1(c) of the Patent License Agreement. Licensor will invoice Licensee for such fees in accordance with the stated
schedule (i.e., thirty days prior to the due date). Such invoices will be due and payable within thirty (30) days from the date of invoice 

  

	 	(d)	Sublicense Fees. Licensee will pay Sublicense Fees indicated in Section 3.1(d) of the Patent License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter. 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-10		Agreement No. PM1401601

	 	(e)	Assignment Fee. Except as otherwise set forth in this section 3.1(e), in the event Licensee assigns this Patent License Agreement to a third party that is not an Affiliate of Licensee, Licensee will pay the
Assignment Fee forth in Section 3.1(e) of this Agreement within 15 days of the effective date of such assignment. Notwithstanding the foregoing, [***] an Assignment Fee shall not be due for assignments of this Patent License Agreement to an
Affiliate of Licensee; provided, however, that if such Affiliate ceases to be an Affiliate of Licensee, then an Assignment Fee shall become due and payable to Licensor within 15 days after such Affiliate ceases to be an Affiliate of Licensee.
Assignments are further governed by Section 15 below. 

  

	 	3.2.	Royalties 

  

	 	(a)	Licensee will pay a running royalty at the rate set forth in Section 3.2 of the Patent License Agreement on [***], payable on or before the Quarterly Payment Deadline for such Contract Quarter, subject to the
following: 

  

	 	(b)	No more than one royalty shall be paid to Licensor hereunder with respect to the Sale of any one unit of Licensed Product whether or not more than one patent or Valid Claim is applicable to the Licensed Product, or the
development, manufacture, or performance thereof. 

  

	 	(c)	If (i) a Licensed Product cannot be made or used without also using patent(s) or patent application(s) owned, licensed, or controlled by a third party in any country of the Territory, and Licensee, an Affiliate, or
any Sublicensee licenses such third party patent(s) or patent application(s) in order to minimize, mitigate, or avoid the risk of infringement-related litigation with respect to the manufacture, use, sate, marketing or provision of a Licensed
Product in any country of the Territory, then Licensee shall be entitled to deduct [***] of the consideration paid to any such third party for any such rights in a particular country (such consideration, “Third Party Royalties”) from any
payments due Licensor under Section 3.2(a) of this Agreement for the infringing Net Sales in that particular country, provided that such amounts payable shall not be reduced, with respect to any Contract Quarter below [***] of the amounts
otherwise due Licensor with respect to such Contract Quarter for said Net Sales without such offset (with any amount of any such consideration not used to reduce payments due Licensor hereunder as a result of such limit remaining available for
deduction from amounts due Licensor in future Contract Quarter for the infringing Net Sales in that particular country, subject to such [***] limit in each Contract Quarter)or (ii) Licensee, an Affiliate, or any Sublicensee licenses such third
party patent(s) or patent 

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-11		Agreement No. PM1401601

	 	
application(s) where such Licensee, Affiliate, or Sublicensee reasonably determines that it is necessary or advisable to obtain a license to any patent(s) or patent application(s) owned,
licensed, or controlled by a Third Party then Licensee shall be entitled to deduct [***] of the consideration paid to any such third party for any such rights in a particular country (such consideration, “Third Party Royalties”) from any
payments due Licensor under Section 3.2(a) of this Agreement for the infringing Net Sales in that particular country, provided that such amounts payable shall not be reduced, with respect to any Contract Quarter below [***] of the amounts
otherwise due Licensor with respect to such Contract Quarter for said Net Sales without such offset (with any amount of any such consideration not used to reduced payments due Licensor hereunder as a result of such limit remaining available for
deduction from amounts due Licensor in future Contract Quarter for the infringing Net Sales in that particular country, subject to such [***] limit in each Contract Quarter). 

 

	 	(d)	Should a compulsory license be granted, or be the subject of a possible grant, to a third party under the applicable laws, rules, regulations, guidelines, or other directives of any Government in the Territory under the
Patent Rights, the Party receiving notice thereof or otherwise becoming aware thereof shall promptly notify the other Party thereof including any material information concerning such compulsory license, and the total amount payable under
Section 3.2(a) with respect to sales of Licensed Products in such country will be adjusted to match any lower amount such third party may be allowed to pay with respect to the sales of such Licensed Products in such country, with such lower
amount subject to further adjustments pursuant to Sections 3.2(c) above. 

  

	 	(e)	Subject to any earlier termination of this Agreement, amounts due under Section 32(a) shall only be payable on a country-by-country and Licensed Product-by-Licensed Product basis for Licensed Products that are made
or sold in a particular country prior to the first date on which there are no Valid Claims of any Patent Right Covering such Product in such country, (such period for a particular Licensed Product in a particular country, the “Royalty
Term” for such Product in such country) 

  

	 	3.3.	Non-cash Consideration 

  

	 	    	If Licensee receives or anticipates receipt of non-cash consideration from Sales or Sublicenses, the manner in which Licensor will receive its compensation under the Agreement with respect to such non-cash consideration
will be negotiated in good faith and timely agreed to by the Parties. 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-12		Agreement No. PM1401601

	4.	Reports and Plans 

 The reports specified in this Section 4 will be sent to Licensor’s payment
and reporting contact identified in Section 18 (Notices) of the Patent License Agreement. Any special formatting requirements for such reports shall be mutually agreed upon in writing by Licensor and Licensee. 

 

	 	4.1.	Quarterly Payment and Milestone Reports 

  

	 	    	On or before each Quarterly Payment Deadline, Licensee will deliver to Licensor a true and accurate report, certified by an officer of Licensee, giving such particulars of the business conducted by Licensee, its
Affiliates and its Sublicensees (including copies of reports provided by Sublicensees and Affiliates to Licensee) during the preceding Contract Quarter under the Agreement as necessary for Licensor to account for Licensee’s payments hereunder,
even if no payments are due. The reports shall continue to be delivered after the termination or expiration of the Agreement until such time as all Licensed Products permitted to be sold after termination or expiration have been sold or destroyed.
Licensee shall provide information in sufficient detail to enable the royalties payable hereunder to be determined and to calculate all of the amounts payable under the Agreement. The report shall include: 

 

	 	(a)	The name of the Licensee, the Patent License Agreement number, and the period covered by the report; 

  

	 	(b)	The name of any Affiliates and Sublicensees whose activities are also covered by the report; 

  

	 	(c)	Identification of each Licensed Product for which any royalty payments have become payable; 

  

	 	(d)	Net Product Sales segregated on a product-by-product basis, and a country-by-country basis, or an affirmative statement that no Sales were made. The report shall also itemize the permitted deductions from the gross
revenue used to arrive at the resulting Net Product Sales on a product-by-product basis; 

  

	 	(e)	The applicable royalty rate; 

  

	 	(f)	An affirmative statement of whether any milestones with deadlines in that Contract Quarter under Section 2.4 and any milestones under Section 3.1(b) were met or not, and the resulting Milestone Fee payable;

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-13		Agreement No. PM1401601

	 	(g)	Non-Royalty Sublicensing Consideration received by Licensee segregated on a Sublicense-by-Sublicense basis, or an affirmative statement that none was received; 

 

	 	(h)	If any consideration was received in currencies other than U.S. dollars, the report shall describe the currency exchange calculations; and 

 

	 	(i)	Any changes in accounting methodologies used to account for and calculate the items included in the report since the previous report. 

 

	 	4.2.	Annual Written Progress Report and Commercialization Plan 

  

	 	    	Within 45 days following the end of each Contract Year until the year following the year in which the first commercial sale of a Licensed Product occurred , Licensee will deliver to Licensor a true and accurate written
progress report and commercialization plan, certified by an officer of Licensee, that summarizes (i) Licensee’s efforts and accomplishments during the Contract Year to diligently commercialize Licensed Products, and
(ii) Licensee’s development and commercialization plans with respect to Licensed Products for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees. The report shall contain the following
information to the extent relevant to the activities under the Agreement: 

  

	 	(a)	The name of the Licensee, the Patent License Agreement number, the names of any Affiliates and Sublicensees, and the products and services being developed and/or commercialized; 

 

	 	(b)	The progress toward completing and the plans for completing the applicable milestone events pursuant to Sections 2.4 and 3.1(b); 

  

	 	(c)	The research and development activities, including status and plans for obtaining any necessary governmental approvals, performed during the past year, and the plans for research and development activities for the next
year; and 

  

	 	(d)	The marketing activities for the past year and planned for the next year, and Licensee’s internal estimate for sales for the next year. 

 

	5.	Payment, Records, and Audits 

  

	 	5.1.	Payments 

  

	 	    	All amounts referred to in the Patent License Agreement are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any kind. Each payment will reference the agreement number set forth
at the beginning of the Patent License Agreement. All payments to Licensor will be made in U.S 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-14		Agreement No. PM1401601

	 	
dollars by check or wire transfer (Licensee to pay all wire transfer fees) payable to the payee identified in Section 18 of the Patent License Agreement and sent to the payment and reporting
contact in Section 18 (Notices) of the Patent License Agreement. 

  

	 	5.2.	Sales Outside the U.S. 

  

	 	    	If any currency conversion shall be required in connection with the calculation of payments hereunder, such conversion shall be made using the rate used by Licensee for its financial reporting purposes in accordance
with Generally Accepted Accounting Principles (or foreign equivalent) or, in the absence of such rate, using the average of the buying and selling exchange rate for conversion between the foreign currency and U.S. Dollars, for current transactions
as reported in The Wall Street Journal on the last business days of the Contract Quarter to which such payment pertains. Licensee may not make any tax withholdings from payments to Licensor, but Licensor agrees to supply to Licensee, upon written
request, appropriate evidence from appropriate U.S, governmental agencies showing that Licensor is a resident of the United States of America for purposes of the U.S. income tax laws and is tax-exempt under such income tax laws. 

 

	 	5.3.	Late Payments 

  

	 	    	Undisputed amounts that are not paid when due will accrue a late charge from the due date until paid, at a rate equal to 1.0% per month (or the maximum allowed by law, if less). 

 

	 	5.4.	Records 

  

	 	    	For a period of four years after the Contract Quarter to which the records pertain, Licensee agrees that it and its Affiliates and Sublicensees will each keep complete and accurate records of their Net Product Sales,
Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient detail to enable such payments to be determined and audited. 

  

	 	5.5.	Auditing 

  

	 	    	Licensee and its Affiliates will permit an independent certified public accountant designated by Licensor and approved by Licensee (which approval shall not be unreasonably withheld or delayed)„ at Licensor’s
expense, to examine books, ledgers, and records relating solely to amounts payable hereunder, during regular business hours, at Licensee’s or its Affiliate’s place of business, on at least 30 days advance notice, to the extent necessary to
verify any payment required under the Agreement. For each Sublicensee, Licensee shall obtain such audit rights for Licensor or itself. If Licensee obtains such audit rights for itself, it will promptly conduct an audit of the Sublicensee’s
records upon Licensor’ s request and at Licensors expense, and Licensee will furnish to Licensor a copy of the findings from such audit. No more than one audit of Licensee, each Affiliate, and each 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-15		Agreement No. PM1401601

	 	
Sublicensee shall be conducted under this Section 5.5 in any calendar year. If any amounts due. Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount of such
underpayment plus accrued interest due in accordance with Section 5.3, If the amount of underpayment is equal to or greater than 5% of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits may
if mutually agreed upon in writing by Licensor and Licensee, consist of a self-audit conducted by Licensee at Licensor’s expense and certified in writing by an authorized officer of Licensee. If the amounts due Licensor have been overpaid, the
balance of overpayment shall be credited toward the next payment of monies owed Licensor. All information examined pursuant to this Section 5.5 shall be deemed to be the Confidential Information of the Licensee. Further, whenever Licensee
and/or its Affiliates and Sublicensees has its books and records audited by an independent certified public accountant Licensee and/or its Affiliates and Sublicensees will within 30 days of the conclusion of such audit, provide Licensor with a
written statement of said auditor, setting forth the calculation of amounts due to Licensor over the time period audited, as determined from the books and records of the Licensee, Affiliate or Sublicensee; but said auditor does not need to give any
audit opinion with said statement. 

  

	6.	Patent Expenses and Prosecution 

  

	 	6.1.	Patent Expenses 

  

	 	    	Licensee shall reimburse Licensor for all past documented, out-of-pocket expenses incurred by Licensor for filing, prosecuting, enforcing, defending and maintaining Patent Rights and related patent searches through the
Effective Date of the Agreement, including those identified in Section 3.1(a) of the Patent License Agreement, and all such future expenses incurred by Licensor, for so long as, and in such countries as the Agreement remains in effect. Licensee
will reimburse such Patent expenses, within 30 days after Licensee’s receipt of an invoice, with such payment being made either directly to Prosecution Counsel or to Licensor, as elected by Licensor in writing on or before the date of the
applicable invoice. Patent expense payment delinquencies (whether owed directly to Prosecution Counsel or to Licensor) that are not in disputed in good faith will be considered a payment default under Section 7.3(a). 

 

	 	6.2.	Direction of Prosecution 

  

	 	    	Licensor will apply for, prosecute, and maintain during the term of this Agreement, the Patent Rights in the United States and in the foreign countries listed in Schedule 6.2 hereto. Licensor will confer with Licensee
to develop a strategy for the prosecution and maintenance of Patent Rights. Licensor will request that copies of all documents prepared by the Prosecution Counsel for submission to governmental patent offices be provided to Licensee for review and
comment prior to filing, to the extent practicable under the circumstances. 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-16		Agreement No. PM1401601

	 	Licensee will be given reasonable opportunities to advise Licensor in the filing, prosecution, and maintenance of Patent Rights. At Licensee’s request and reasonably in advance of any filing, fee, or other action
deadlines, Licensee shall be provided with copies of all prosecution documents relating to Patent Rights so that Licensee may have the opportunity to offer comments and remarks thereon, such comments and remarks to be given due consideration by
Licensor. At its discretion, Licensor may allow Licensee to instruct Prosecution Counsel directly, provided, that (a) Licensor will maintain final authority in all decisions regarding the prosecution and maintenance of the Patent Rights,
(b) Licensor may revoke this authorization to instruct Prosecution Counsel directly at any time, and (c) the Prosecution Counsel remains counsel to the Licensor with an appropriate contract (and shall not jointly represent Licensee unless
requested by Licensee and approved by Licensor, and an appropriate engagement letter and conflict waiver are in effect). If Licensee wishes to instruct Prosecution Counsel directly or change Prosecution Counsel, Licensee may request to do so by
following the Licensor’s procedures for such Licensor reserves in its sole, discretion the ability to change Prosecution Counsel and to approve or disapprove any requested changes by Licensee. The Parties agree that they share a common legal
interest to get valid enforceable patents and that Licensee will maintain as privileged all information received pursuant to this Section. 

  

	 	6.3.	Ownership 

  

	 	    	All patent applications and patents will be in the name of Licensor (and any co- owner identified in Section 1 of the Patent License Agreement) and owned by Licensor (and such co-owner, if any). No payments due
under the Agreement will be reduced solely as the result of co-ownership interests in the Patent Rights by Licensee or any other party. 

  

	 	6.4.	Additional Foreign Filings 

  

	 	    	If Licensee wishes to pursue patent protection in countries other than the U.S., and the foreign countries listed Schedule 62 hereto, then (i) Licensee shall notify Licensor in writing, subject to applicable bar
dates, of such foreign countries in sufficient time to reasonably enable the preparation of such additional filings, (ii) Licensor will apply for, prosecute, and maintain during the term of this Agreement, the Patent Rights in such foreign
countries, and (iii) Schedule 6.2 shall be automatically amended to include such foreign countries-. If Licensee notifies Licensor in writing that it does not choose to pursue patent, rights in a particular foreign country and Licensor chooses
to do so, Licensor shall so notify Licensee and thereafter said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. 

 

	 	6.5.	Withdrawal from Paying Patent Costs 

  

	 	    	If at any time Licensee wishes to cease paying for any costs for a particular Patent 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-17		Agreement No. PM1401601

	 	
Right or for patent prosecution in a particular jurisdiction, Licensee must give Licensor at least 90 days prior written notice and Licensee will continue to be obligated to pay for the patent
costs which reasonably accrue during said notice period. Thereafter, said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. 

 

	 	6.6.	U.S. Patent and Trademark Office Entity Size Status 

  

	 	    	Licensee represents that as of the Effective Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark Office is as set forth in Section 1 of the Patent License
Agreement. Licensee will inform Licensor in writing on a timely basis of any change in its U.S. Patent and Trademark Office entity size status. 

  

	7.	Term and Termination 

  

	 	7.1.	Term 

  

	 	    	Unless earlier terminated as provided herein, the term of the Agreement will commence on the Effective Date and continue on a country-by-country and Licensed Product-by Licensed Product basis, until the expiration of
the Royalty Term for a particular Licensed Product in a particular country (with the entire Agreement expiring on the expiration of the last-to-expire Royalty Term). 

 

	 	7.2.	Termination by Licensee 

  

	 	    	Licensee, at its option, may terminate the Agreement by providing Licensor written notice of intent to terminate, which such termination effective will be 90 days following receipt of such notice by Licensor.

  

	 	7.3.	Termination by. Licensor 

  

	 	    	Licensor, at its option, may immediately terminate the Agreement, or any part of Patent Rights, or any part of Field, or any part of Territory, or the exclusive nature of the license grant, upon delivery of written
notice to Licensee of Licensor’s decision to terminate, if any of the following occur: 

  

	 	(a)	Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make the required payment within 30 days after delivery of written notice from Licensor; or 

 

	 	(b)	Licensee is in breach of any non-payment provision of the Agreement, and does not cure such breach within 60 days after delivery of written notice from Licensor; or 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-18		Agreement No. PM1401601

	 	(c)	Licensor delivers notice to Licensee of three or more [***] breaches of the Agreement in any nine (9) month period, even in the event that Licensee cures such breaches in the allowed period, [***]; or

  

	 	(d)	Licensee or its Affiliate or Sublicensee participates in any proceeding or action to challenge the validity, enforceability, or scope of one or more of the Patent Rights. Provided however, this section shall not be
applicable in the context of a Sublicensee or Affiliate defending against a patent infringement suit initiated by licensor, or if Licensee terminates a Sublicensee (in the event Sublicensee sues Licensor) within 30 days of receiving notice from
Licensor that they are being sued by the Sublicensee. 

  

	 	7.4.	Other Conditions of Termination 

  

	 	    	The Agreement will terminate: 

  

	 	(a)	Immediately without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee files for bankruptcy under Chapter 7 or Chapter 11 of the U.S. Bankruptcy Act or becomes insolvent, or
(ii) Licensee’s Board of Directors elects to liquidate its assets or dissolve its business, or (iii) Licensee makes an assignment for the benefit of creditors or (iv) if the business or assets of Licensee are otherwise placed in
the hands of a receiver, assignee for the protection of creditors or trustee, whether by voluntary act of Licensee or otherwise; or 

  

	 	(b)	At any time by mutual written agreement between Licensee and Licensor. 

  

	 	7.5.	Effect of Termination 

  

	 	    	If the Agreement is terminated for any reason: 

  

	 	(a)	If a Sublicensee is in good standing under its Sublicense Agreement without any uncured defaults that would otherwise have entitled the Licensee to terminate such Sublicense, the Sublicensee may request Licensor to
grant a direct license to the Sublicensee on comparable terms; which request must be in writing and received by Licensor not later than thirty (30) days after any termination of the Agreement. If Licensor determines that the Sublicensee is well
qualified to continue as a direct licensee, Licensor will not unreasonably withhold consent for such request; in which event, said Sublicensee and Licensor will enter into a new mutually approved written license agreement that endeavors to preserve
the essential benefits for each party that they enjoyed under the prior Agreement and Sublicense Agreement For the avoidance of doubt, during the period between the termination of the Agreement and the date 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-19		Agreement No. PM1401601

	 	
on which such a mutually approved written license agreement is consummated between the Sublicensee and Licensor, the Sublicense shall be deemed to continue with the Licensor directly. If no such
mutually approved written license agreement is consummated between the Sublicensee and Licensor, the Sublicense shall be deemed to be terminated. 

  

	 	(b)	Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to sell, leasing, loaning and importing any licensed Products by the effective date of termination; and

  

	 	(c)	Licensee shall tender payment of all accrued royalties and other payments due to Licensor in accordance with the payment terms hereof; and 

 

	 	(d)	Nothing in the Agreement will be construed to release either Party from any obligation that matured prior to the effective date of termination; and 

 

	 	(e)	The provisions of Sections 8 (Confidentiality), 9 (Infringement and Litigation), 11 (Representations and Disclaimers), 12 (Limit of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and
19 (General Provisions) will survive any termination or expiration of the Agreement In addition, the provisions of Sections 3 (Compensation), 4.1 (Quarterly Payment and Milestone Reports), 5 (Payment, Records and Audits), and 6.1 (Patent Expenses)
shall survive with respect to all activities and payment obligations accruing prior to the termination or expiration of the Agreement. 

  

	8.	Confidentiality 

  

	 	8.1.	Definition 

  

	 	    	“Confidential Information” means all information that is of a confidential and proprietary nature to Licensor or Licensee and provided by one Party to the other Party under the Agreement. 

 

	 	8.2.	Protection and Marking 

  

	 	    	Licensor and Licensee each agree that all Confidential Information disclosed in tangible form, and marked “confidential” and forwarded to one by the other, or if disclosed orally, is designated as confidential
at the time of, disclosure: (i) is to: be held in strict confidence by the receiving Party, (ii) is to be used by and under authority of the receiving Party only as authorized in the Agreement, and (iii) shall not be disclosed by the
receiving Party, its agents or employees without the prior written consent of the disclosing Party or as authorized in the Agreement. Licensee has the right to use and disclose Confidential Information of Licensor reasonably 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-20		Agreement No. PM1401601

	 	
in connection with the exercise of its rights under the Agreement, including without limitation disclosing to Affiliates, Sublicensees, potential investors, acquirers, and others on a need to
know basis, if such Confidential Information is provided under conditions which reasonably protect the confidentiality thereof. Each Party’s obligation of confidence hereunder includes, without limitation, using at least the same degree of care
with the disclosing Party’s Confidential Information as it uses to protect its own Confidential Information, but always at least a reasonable degree of care. 

 

	 	8.3.	Confidentiality of Terms of Agreement 

  

	 	    	Each Party agrees not to disclose to any third party the terms of the Agreement without the prior written consent of the other Party hereto, except each Party may disclose the terms of the Agreement: (a) to
advisors, actual or potential Sublicensees, acquirers or investors, and others on a need to know basis, in each case, under appropriate confidentiality obligations substantially similar to those of this Section 8; and (b) to the extent
necessary to comply with applicable laws and court orders (including, without limitation, The Texas Public Information Act, as may be amended from time to time, other open records laws, decisions and rulings, and securities laws, regulations and
guidance). If the Agreement is not for all fields of use then Licensor may disclose the Field to other potential third party licensees. Notwithstanding the foregoing, the existence of the Agreement shall not be considered Confidential Information.

  

	 	8.4.	Disclosure Required by Court Order or Law 

  

	 	    	If the receiving Party is required to disclose Confidential Information of another Party hereto, or any terms of the Agreement pursuant to the order or requirement of a court, administrative agency, or other
governmental body or applicable law, the receiving Party may disclose such Confidential Information or terms to the extent required, provided that the receiving Party shall use reasonable efforts to provide the disclosing Party with reasonable
advance notice thereof to enable the disclosing. Party to seek a protective order and otherwise seek to prevent such disclosure. To the extent that Confidential Information so disclosed does not become part of the public domain by virtue of such
disclosure, it shall remain Confidential Information protected pursuant to Section 8. 

  

	 	8.5.	Copies 

  

	 	    	Each Party agrees not to copy or record any of the Confidential Information of the other Party, except as reasonably necessary to exercise its rights or perform its obligations under the Agreement, and for archival and
legal purposes. 

  

	 	8.6.	Continuing Obligations 

  

	 	    	Subject to the exclusions listed in Section 8.7, the Parties’ confidentiality obligations under the Agreement will survive termination of the Agreement and will continue for a period of five years thereafter.

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-21		Agreement No. PM1401601

	 	8.7.	Exclusions 

  

	 	    	Information shall not be considered Confidential Information of a disclosing Party under the Agreement to the extent that the receiving Party can establish by competent written proof that such information:

  

	 	(a)	Was in the public domain at the time of disclosure; or 

  

	 	(b)	Later became part of the public domain through no act or omission of the recipient Party, its employees, agents, successors or assigns in breach of the Agreement; or 

 

	 	(c)	Was lawfully disclosed to the recipient Party by a third party having the right to disclose it not under an obligation of confidentiality; or 

 

	 	(d)	Was already known by the recipient Party at the time of disclosure; or 

  

	 	(e)	Was independently developed by the recipient Party without use of the disclosing Party’s Confidential Information. 

  

	 	8.8.	Copyright Notice 

  

	 	    	The placement of a copyright notice on any Confidential Information will not be construed to mean that such information has been published and will not release the other Party from its obligation of confidentiality
hereunder 

  

	9.	Infringement and Litigation 

  

	 	9.1.	Notification 

  

	 	    	If either Licensors designated office for technology commercialization or Licensee becomes aware of any alleged, potential or actual infringement of Patent Rights, each Party shall promptly notify the other of such in
writing. Within two (2) business days of such notification (the “SRA Notice Period”), Licensor agrees to notify Licensee in writing if the infringing party is a party to a sponsored research agreement with the Licensor [***].

  

	 	9.2.	Licensee’s Enforcement Rights 

  

	 	    	With respect to any actual, potential, or alleged infringement of the Patent Rights, which shall include, to the extent permitted under applicable law, Licensee shall have the first and primary right, but not the
obligation, to at its expense, initiate, prosecute, and control any action or legal proceedings, and/or enter into a settlement, including any declaratory judgment action, with respect thereto. In the event Licensor provides Licensee with an SRA
Notice during the SRA Notice 

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-22		Agreement No. PM1401601

	 	
Period, Licensee shall not file an infringement lawsuit against the third party identified in such SRA Notice for at least [***] from the date of such SRA Notice. In any such litigation brought
by Licensee, Licensee shall have the right to use and sue in Licensor’s name and join Licensor as a party to such litigation, only with the prior written consent of Licensor; and Licensor shall cooperate reasonably with respect thereto, as
requested and expense of Licensee. It within one hundred eighty (180) Calendar Days of the notice in Section 9.1, Licensee shall not have brought and shall not be diligently prosecuting an infringement or other action with respect to such
actual, potential, or alleged infringement, then Licensor shall have the right, at its expense, to bring suit to enforce such. Patent Rights against such actual, alleged, or potential infringer, at its own expense, unless Licensee has provided
Licensor with a mutually agreeable reasonable strategic rationale for not taking action to terminate such actual, potential, or alleged infringement, not to be unreasonably denied Notwithstanding the foregoing, Licensor shall not, and shall not
permit any third party to proceed against an alleged infringer of the Patent Rights in the Territory (1) unless significant damages are reasonably expected to be recovered from the infringer in such proceeding and (2) without first
consulting with Licensee regarding the strategy for such proceeding and considering in good faith Licensee’s comments regarding such proceeding. 

  

	 	9.3.	Litigation Control. The Party pursuing or controlling any action or defense under Section 9.2 (the ‘Controlling Party”) shall be free to enter into a settlement, consent judgment, or other
voluntary disposition of any such action or defense, provided, however, that (i) the Controlling Party shall consult with the other Party (the “Secondary Party”) prior to entering into any settlement or voluntary disposition thereof,
(ii) any settlement, consent judgment or other voluntary disposition of such actions which (1) subjects the Secondary Party to any non-indemnified liability or obligation or (2) admits fault or wrongdoing on the part of Secondary
Party must, in each case, be approved in advance and in writing by the Secondary Party, (iii) any settlement consent judgment or other voluntary disposition of such actions which materially limits the scope, validity, or enforceability of, or
otherwise may adversely affect, any Licensor Patents shall not be entered into, consented to, approved, or agreed upon without the other Party’s prior written approval, and (iv) any settlement, consent judgment or other voluntary
disposition of such actions that would reasonably be expected to materially adversely affect the Patent Rights or the ability of Licensee to manufacture, use, market or sell Licensed Products shall not be, entered into, consented to, approved, or
agreed upon without Licensee’s prior written consent. With respect to clause (ii) or (iii) above in this Section 93, the Secondary Party shall provide the Controlling Party notice of its approval or denial of such approval within
[***] Business Days of any request for such approval by the Controlling Party, provided that (X) in the event Secondary Party wishes to deny such approval, such notice shall include a written description summarizing the 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-23		Agreement No. PM1401601

	 	
Secondary Party’s reasonable objections to the proposed settlement consent judgment or other voluntary disposition and (Y) Secondary Party shall be deemed to have approved such proposed
settlement, consent judgment, or other voluntary disposition in the event it fails to provide such notice within such [***] Business Day period. 

  

	 	9.4.	Sharing Net Recovery. Any recovery or damages received by the Controlling Party with respect to the infringement of the rights to Licensor Patents granted under this Agreement, or in settlement of any
matter subject to Section 9.2. shall (I) first be used to reimburse the Parties for unreimbursed reasonable, documented expenses (excluding, with respect to any costs or expenses incurred by Licensor, compensation of any employees or
consultants of Licensor or any Affiliate thereof) incurred in connection with such action or settlement, and the remainder shall be split [***] to Controlling Party and [***] to Secondary Party Notwithstanding the foregoing, the Secondary Party, at
its expense, shall have the right to be represented by counsel of its choice in any proceeding governed by this Section 91. 

  

	10.	Export Compliance 

  

	    	Licensee understands that the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration Act (EAA), including its Export Administration
Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (a) ITAR and EAR
product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR end user-specific requirements; (d) Foreign Corrupt Practices Act; and (e) anti- boycott laws and
regulations. Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable US. laws and regulations) pertaining to the Licensed Products (including any associated products, items,
articles, computer software, media, services, technical data and other information). Licensee certifies that it will not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Licensed
Products (including any associated products, items, articles, computer software, media, services, technical data and other information) in violation of applicable U.S. laws and regulations. Licensee will include a provision in its agreements,
substantially similar to this Section 10, with its Sublicensees, third party wholesalers and distributors, and physicians, hospitals or other healthcare providers who purchase a Licensed Product, requiring that these parties comply with all
then-current applicable US, export laws and regulations and other applicable U.S. laws and regulations. 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-24		Agreement No. PM1401601

	11.	Representations and Disclaimers 

  

	 	11.1.	Licensor Representations 

  

	 	    	Except for the rights, if any, of the Government as set forth in Section 11.2, Licensor represents and warrants to Licensee that to the knowledge of Licensor’s Office of Technology Commercialization
(i) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights (other than the right, title and interest of any joint owner identified in Section 1 of the Patent License Agreement), (ii) Licensor
has the right to grant licenses hereunder, (iii) Licensor has not knowingly granted and will not knowingly grant licenses or other rights under the Patent Rights that are in conflict with the terms and conditions in the Agreement,
(iv) Licensor’s execution and performance of this Agreement will not result in a breach of any other contract to which it is, or will become, a party, and (v) OTC has not received any written notification, alleging that the Patent Rights
are invalid or unenforceable or that the exercise by Licensee of any rights granted hereunder will infringe on or constitute misappropriation of any patent or other proprietary right of any third party. 

 

	 	11.2.	Government Rights 

  

	 	    	Licensee understands that Patent Rights may have been developed under a funding agreement with Government and, if so, that Government may have certain rights relative thereto. The Agreement is made subject to the
Government’s rights under any such agreement and under, any applicable Government law or regulation. To the extent that there is a conflict between any such agreement, such applicable law or regulation and the Agreement, the terms of such
Government agreement, and applicable law or regulation, shall prevail. Licensee agrees that, to the extent required by U.S. laws and regulations, Licensed Products used or sold in the U.S. will be manufactured substantially in the U.S., unless a
written waiver is obtained in advance from the U.S. Government. 

  

	 	11.3.	Licensor Disclaimers 

  

	 	    	EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED
PRODUCTS OR LICENSED SERVICES, OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE, MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, AND/OR BREADTH OF PATENT
RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-25		Agreement No. PM1401601

	 	
LICENSOR THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY
PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS. LICENSOR HAS NO OBLIGATION TO FURNISH TO LICENSEE ANY KNOW-HOW, TECHNOLOGY OR TECHNOLOGICAL INFORMATION.

  

	 	11.4.	Licensee Representation 

  

	 	    	By execution of the Agreement, Licensee represents, acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by Licensor or its employees to enter into the Agreement, and (b) that
Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items and issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the Agreement; and (c) that
Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due diligence, and (c) that Licensee accepts all risks inherent herein. Licensee represents that it is a duly
organized, validly existing entity of the form indicated in Section 1 of the Patent License Agreement, and is in good standing under the laws of its jurisdiction of organization as indicated in Section 1 of the Patent License Agreement and has
all necessary corporate or other appropriate power and authority to execute, deliver and perform its obligations hereunder. 

  

	12.	Limit of Liability 

  

	    	IN NO EVENT SHALL. LICENSOR, THE UNIVERSITY SYSTEM IT GOVERNS, ITS MEMBER INSTITUTIONS, INVENTORS, REGENTS, OFFICERS, EMPLOYEES, STUDENTS, AGENTS OR AFFILIATED ENTERPRISES (COLLECTIVELY, “LICENSOR COVERED
PARTIES”), BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT
MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. 

  

	    	OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION PROVIDED UNDER SECTION 13 WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL LICENSEE, ITS AFFILIATES OR SUBLICENSEES BE LIABLE TO LICENSOR COVERED PARTIES
FOR ANY INDIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL EXEMPLARY OR PUNITIVE DAMAGES 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-26		Agreement No. PM1401601

	 	
(INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR SHOULD
HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES. 

  

	13.	Indemnification 

  

	 	13.1.	Indemnification Obligation 

  

	 	    	Subject to Section 132, Licensee agrees to hold harmless, defend and indemnify Licensor, the university system it governs, its member institutions, its Regents, officers, employees, students and agents (the
“Indemnified Parties”, or an “Indemnified Party”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs and expenses (including, without limitation, reasonable
attorneys’ fees and other expenses of litigation) (collectively “Liabilities”) resulting from claims or demands brought by third parties against an Indemnified Party on account of any injury or death of persons, damage to property, or
any other damage or loss arising out of the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or third party wholesalers or distributors, or physicians, hospitals or other healthcare providers who purchase
a Licensed Product, of the rights granted hereunder. 

  

	 	13.2.	Conditions of Indemnification 

  

	 	    	Licensee shall have no responsibility or obligation under Section 13.1 for any Liabilities to the extent caused by the gross negligence or willful misconduct by an Indemnified Party. Obligations to indemnify, and
hold harmless under Section 13.1 are subject to (a) to the extent authorized by the Texas Constitution and the laws of the State of Texas, and subject to the statutory duties of the Texas Attorney General, the Indemnified Party giving
Licensee control of the defense and settlement of the claim and demand; and (b) to the extent authorized by the Texas Constitution and the laws of the State of Texas and subject to statutory duties of the Texas Attorney General, the Indemnified
Party providing assistance reasonably requested by Licensee, at Licensee’s expense. 

  

	14.	Insurance 

  

	 	14.1.	Insurance Requirements 

  

	 	    	Prior to any Licensed Product being used in humans or sold (including for the purpose of obtaining regulatory approvals), by Licensee, an Affiliate, or by a Sublicensee, and for a period of five years after the
Agreement expires or is terminated, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance or an equivalent program of self-insurance in commercially reasonable and appropriate amounts for the
Licensed Product being used or sold. Licensee shall use commercially reasonable efforts to have 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-27		Agreement No. PM1401601

	 	
Licensor named as an additional insured party. Such commercial general liability insurance shall provide, without limitation: (I) product liability coverage; (ii) broad form contractual
liability coverage for Licensee’s indemnification under the Agreement; and (iii) coverage for litigation costs. 

  

	 	14.2.	Evidence of Insurance and Notice of Changes 

  

	 	    	Upon request by Licensor, Licensee shall provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide Licensor with written notice of at least 30 days prior to Licensee cancelling, not
renewing, or materially changing such insurance. 

  

	15.	Assignment 

  

	    	The Agreement may not be assigned by Licensee without the prior written consent of Licensor, which consent will not be unreasonably withheld; provided, however, that Licensee shall be permitted to assign this Agreement
to (i) any of its Affiliates and [***] A merger or other transaction (excluding equity financings of Aeglea BioTherapeutics Holdings, LLC and its Affiliates) in which the equity holders of Licensee prior to such event hold less than a majority
of the equity of the surviving or acquiring entity shall be considered an assignment of the Agreement. For any permitted assignment to be effective, (a) the Licensee must be in good standing under this Agreement, (b) the assignment fee
shall be payable as specified in Section 3,1(e) of the Agreement (c) the assignee must assume in writing all of Licensee’s interests, rights, duties and obligations under the Agreement and agree to comply with all terms and conditions
of the Agreement as if the assignee were an original Party to the Agreement (d) provide written notice to the Licensor of such assignment no less than 15 days after completion of such assignment Any such assignment must be of all rights and
obligations of Licensee, such that there is only one existing Licensee at any one time. 

  

	16.	Governmental Markings 

  

	 	16.1.	Patent Markings 

  

	 	    	To the extent reasonably practical, Licensee agrees to mark, and shall use commercially reasonable efforts to ensure that its Affiliates, licensees, and sublicensees mark, all Licensed Products with the number of any
applicable patent(s) licensed hereunder as part of the Patent Rights in accordance with each country’s patent marking laws, including Title 35, U.S. Code, or if such marking is not practicable, shall so mark the accompanying outer box or
product insert for Licensed Products accordingly. 

  

	 	16.2.	Governmental Approvals and Marketing of licensed Products 

  

	 	    	Licensee will be responsible for obtaining all necessary Governmental approvals for the development production, distribution, sale, and use of any Licensed 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-28		Agreement No. PM1401601

	 	
Product, at Licensee’s expense, including, without limitation, any safety studies, Licensee will have sole responsibility for any warning labels, packaging and instructions as to the use and
the quality control for any Licensed Product. 

  

	 	16.3.	Foreign Registration and Laws 

  

	 	    	Licensee agrees to register the Agreement with any foreign governmental agency that requires such registration; and Licensee will pay all costs and legal fees in connection with such registration. Licensee is
responsible for compliance with all foreign laws affecting the Agreement or the Sale of Licensed Products to the extent there is no conflict with United States law, in which case, United States law will control. 

 

	17.	Use of Name 

  

	    	Licensee will not use the name, trademarks or other marks of Licensor (or the name of the university system it governs, its member institutions; any of its Regents or employees) without the advance written consent of
Licensor; provided however, in connection with describing the Agreement to existing and prospective investors and Sublicensees, Licensee may identify Licensor’s name as the licensor. Licensor may use Licensee’s name and logo for annual
reports, brochures, website, and internal reports without prior consent. 

  

	18.	Notices 

  

	    	Any notice or other communication of the Parties required or permitted to be given or made under the Agreement will be in writing and will be deemed effective when sent in a manner that provides confirmation or
acknowledgement of delivery and received at the address set forth in Section 18 of the Patent License Agreement (or as changed by written notice pursuant to this Section 18). Notices required under the Agreement may be delivered via E-mail
provided such notice is confirmed in writing as indicated. 

  

	    	Notices shall be provided to each Party as specified in the “Contact for Notice” address set forth in Section 18 of the Patent License Agreement. Each Party shall update the other Party in writing with
any changes in such contact information. 

  

	19.	General Provisions 

  

	 	19.1.	Binding Effect 

  

	 	    	The Agreement is binding upon and inures to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and permitted successors in interest. 

 

	 	19.2.	Construction of Agreement 

  

	 	    	Headings are included for convenience only and will not be used to construe the 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-29		Agreement No. PM1401601

	 	
Agreement. The Parties acknowledge and agree that both Parties substantially participated in negotiating the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the
Agreement shall not be construed more favorably toward one Party than the other Party, regardless of which Party primarily drafted the Agreement. 

  

	 	19.3.	Counterparts and Signatures 

  

	 	    	The Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. A Party may evidence its execution and
delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or email. 

  

	 	19.4.	Compliance with Laws 

  

	 	    	Licensee will comply with all applicable federal, state and local laws and regulations, including, without limitation, all export laws and regulations. 

 

	 	19.5.	Governing Law 

  

	 	    	The Agreement will be construed and enforced in accordance with laws of the U.S. and the State of Texas, without regard to choice of law and conflicts of law principles. 

 

	 	19.6.	Modification 

  

	 	    	Any modification of the Agreement will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No modification will be made by email communications. 

 

	 	19.7.	Severability 

  

	 	    	If any provision hereof is held to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects
the original intent of the Parties, and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such
invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other provisions in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable. 

 

	 	19.8.	Third Party Beneficiaries 

  

	 	    	Nothing in the Agreement, express or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties and their permitted successors and assigns. However, if there is a joint owner
of any Patent Rights identified in Section 1 of the Patent License Agreement (other than Licensee), then 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-30		Agreement No. PM1401601

	 	
Licensee hereby agrees that the following provisions of these Terms and Conditions extend to the benefit of the co- owner identified therein (excluding the Licensee to the extent it is a
co-owner) as if such co-owner was identified in each reference to the Licensor but only if such co-owner is bound by all of Licensor’s obligations under this Agreement: the retained rights under clause (b) of Section 2.1;
Section 113 (Licensor Disclaimers); Section 12 (Limitation of Liability); Section 13 (Indemnification); Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if
applicable). 

  

	 	19.9.	Waiver 

  

	 	    	Neither Party will be deemed to have waived any of its rights under the Agreement unless the waiver is in writing and signed by such Party. No delay or omission of a Party in exercising or enforcing a right or remedy
under the Agreement shall operate as a waiver thereof. 

  

	 	19.10.	Sovereign Immunity 

  

	 	    	Nothing in the Agreement shall be deemed or treated as any waiver of Licensor’s sovereign immunity. 

  

	 	19.11.	Entire Agreement 

  

	 	    	The Agreement constitutes the entire Agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings relative to such matters.

  

	 	19.12.	Claims Against Licensor for Breach of Agreement 

  

	 	    	Licensee acknowledges that any claim for breach of the Agreement asserted by Licensee against Licensor shall be subject to Chapter 2260 of the Texas Government Code and that the process provided therein shall be
Licensee’s sole and exclusive process for seeking a remedy for any and all alleged breaches of the Agreement by Licensor or the State of Texas. 

  

	 	19.13.	Grant of Security Interest 

  

	 	    	Licensee hereby grants to Licensor a security interest in and to Licensee’s rights under the Patent License Agreement, as collateral security for the payment by Licensee of any and all sums which may be owed from
time to time by Licensee to Licensor. Licensor shall have all rights of a secured party as specified in the Texas Uniform Commercial Code relative to this security interest and the enforcement thereof. Licensee hereby authorizes Licensor to file
with the appropriate governmental agencies appropriate UCC-1 financing statements to evidence this security interest. 

 END OF
EXHIBIT A 
  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Licensee: AEMase Inc.		CONFIDENTIAL		Exclusive PLA
	The University of Texas at Austin		Page A-31		Agreement No. PM1401601

 SCHEDULE 6.2 

FOREIGN COUNTRIES FOR PATENT FILINGS 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

 SCHEDULE 20.2 
  

Patents 
  

			
	“Compositions of Engineered Human Arginases and Methods for Treating Cancer”
	Serial No. 8,440,184		United States

 Patent Applications 
  

			
	“Arginase formulations and methods”
	Serial No. 13/380,776		United States
	Serial No. PCT/US2010/040205		International
	Serial No. 61/221,396		United States
	Serial No. 10800270.0 (Publication No. EP2449102)		European Patent Office
	Serial No. 12111085.9		Hong Kong
	Serial No. 2012-517824		Japan
	Serial No. 2,766,039		Canada
	“Engineered Enzymes with Methionine-Gamma-Lyase Enzymes and Pharmacological Preparations Thereof”		 
	Serial No. 61/301,368		United States
	Serial No. 13/020,268		United States
	Serial No. PCT/US2011/023606		International
	Serial No. 2011212885		Australia
	Serial No. 2,788,689		Canada
	Serial No. 201180013307.X		China
	Serial No. 11740355		European Patent Office
	Serial No. 2012-552084		Japan
	Serial No. 10-2012-7023176		Republic of Korea
	Application No. 13106011,7 (GGE0,13004CHK)		Hong Kong
	 “Compositions of Engineered Human
Arginases and Methods for Treating Cancer”
		 
	Serial No. 12/610,685		United States
	Serial No. 61/110,218		United States
	Application No. 13/863,448 (GGEO.P002US.C1)		United States
	Serial No. PCT/US2009/062969		International
	Serial No. 09824219.1 (Publication No. EP2350273)		European Patent Office
	Serial No. 12100429.7		Hong Kong
	Serial No. 2,742,497		Canada
	Serial No. 2011-534855 (Publication No. JP2012507301)		Japan
	Application No. 2013-241687 (GGEO.P002US.C1)		Japan
	“Engineering of L-Cysteine/L-Cystine Degrading Enzymes for Therapeutic Purposes”		 
	Serial No. 61/871,727		United States

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]